1 Zhao S,Li G,Yang L,et al.Response-specffic progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxypmgestemne acetate.Oncol Lett,2013,5:139-144. 2 Creasman WT,Odicino F,Maisonneuve P,et al.Carcinoma of the corpus uteri.J Epidemiol Biostat,2001,6:47-86. 3 Jadoul P,Donnez J.Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma.Fertil Steril,2003,80:1315-1324. 4 Yang HP,Cook LS,Weiderpass E,et al.Infertility and incident endometrial cancer risk:a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2).Br J Cancer,2015,112:925-933. 5 Prakansamut N,Sirayapiwat P,Triratanachat S.The percentages of endometrial hyperplasia and endometrial cancer among polycystic ovary syndrome (PCOS) patients presenting with abnormal menstrual pattern.J Med Assoc Thai,2014,97:159-164. 6 樊艺,韩克,王雪晨,等.孕激素与他莫西芬合用降低子宫内膜癌的风险.中国妇幼健康研究,2008,19:609-611. 7 刘瑶.子宫内膜癌的孕激素拮抗及增敏机制.国际妇产科学杂志,2015,42:104-107. 8 Ballaré C,Vallejo G,Vicent GP,et al.Progesterone signaling in breast and endometrium.J Steroid Bioehem Mol Biol,2006,102:2-10. 9 杨业洲,陈廉.子宫内膜癌的激素治疗.实用医院临床杂志,2005,2:12-14. 10 汪丽萍,乔娟,李海叶,等.16例早期子宫内膜癌患者保留生育功能的疗效观察.临床肿瘤学杂志,2014,19:164-167. 11 Horiuchi S,Kato K,Suga S,et al.Expression of progesterone receptor B is associated with G0/G1 arrest of the cell cycle and growth inhibition in NIH3T3 cells.Exp Cell Res,2005,305:233-243. 12 Gabbara S,Bhagwat AS.The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor.Biochem J,1995,307:87-92. 13 Shang Y.Brown M.Molecular determinants for the tissue specificity of SERMs.Science,2002,295:2465-2458. 14 Neven P,Vergote I.Should tamoxifen users be screened for endometrial lesions? Lancet,1998,351:155-157. 15 刘祖翠,魏莎莉,陈国庆,等.他莫昔芬对子宫内膜癌RL-95-2细胞增殖及let-7g表达的影响.中国生物制品学杂志,2013,26:84-88. 16 苏椿淋,李昕,林金芳,等.子宫内膜不典型增生及早期子宫内膜样癌药物治疗的进展及前景.中华妇产科杂志,2015,50:715-717. 17 Herzog TJ.What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? Gynecol Oncol,2004 ,92:1-3. 18 Whitney CW,Brunetto VL,Zaino RJ,et al.Gynecologic Oncology Group study.Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma:a Gynecologic Oncology Groupstudy.Gynecol Oncol,2004 ,92:4-9. 19 Fiorica JV,Brunetto VL,Hanjani P,et al.Gynecologic Oncology Group study.Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma:a Gynecologic Oncology Group study.Gynecol Oncol,2004 ,92:10-14. 20 李佳.他莫昔芬处理子宫内膜癌细胞后ARID1A、ERα、ERβ、PR、P53变化的研究.河北医科大学,2014. 21 李宏,姜继勇.他莫昔芬与子宫内膜癌.国外医学(妇产科学分册),2005,32:189-191. 22 赵晋,李红霞.年轻未育妇女子宫内膜癌的保守治疗.中华临床医师杂志(电子版),2015,9:363-366. 23 王波,岳天孚.他莫昔芬的妇科效应.国外医学(妇产科学分册),2002,29:49-50.
